Novel fusion nucleic acid sequences and fusion proteins present in human t(2:5) lymphoma, methods of detection and uses thereof (SJ-93-0002)
- *Abstract
-
ALK is a kinase that has been associated with several different cancers. It can be used as a drug screening target, along with the ALK fusion proteins associated with various cancers. ALK and ALK fusion inhibitors are contemplated to be useful as anti-cancer therapeutics. ALK antibodies are also provided.
Key words: ALK, NPM-ALK, kinase, lymphoma, cancer, vaccine
Granted patents and published applications: U.S. Patent Nos. 5,529,925; 5,770,421;6,174,674; 6,451,997 and 6,696,548;Australian Patent No. 679,833; European Patent No. 731,806
Related scientific references: Morris, S.W. et al., "Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in Non-Hodgkin's Lymphoma", Science 263: 1281-1284 (1994);
Passoni, L. et al., "ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes", Blood 99(6): 2100-2106 (2002)
- Country/Region
- USA
